1. Home
  2. LPTX vs BLNK Comparison

LPTX vs BLNK Comparison

Compare LPTX & BLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • BLNK
  • Stock Information
  • Founded
  • LPTX 2011
  • BLNK 2009
  • Country
  • LPTX United States
  • BLNK United States
  • Employees
  • LPTX N/A
  • BLNK N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • BLNK Industrial Specialties
  • Sector
  • LPTX Health Care
  • BLNK Consumer Discretionary
  • Exchange
  • LPTX Nasdaq
  • BLNK Nasdaq
  • Market Cap
  • LPTX 119.6M
  • BLNK 105.2M
  • IPO Year
  • LPTX N/A
  • BLNK N/A
  • Fundamental
  • Price
  • LPTX $0.39
  • BLNK $0.90
  • Analyst Decision
  • LPTX Buy
  • BLNK Buy
  • Analyst Count
  • LPTX 3
  • BLNK 8
  • Target Price
  • LPTX $8.50
  • BLNK $5.24
  • AVG Volume (30 Days)
  • LPTX 321.2K
  • BLNK 4.4M
  • Earning Date
  • LPTX 05-12-2025
  • BLNK 03-13-2025
  • Dividend Yield
  • LPTX N/A
  • BLNK N/A
  • EPS Growth
  • LPTX N/A
  • BLNK N/A
  • EPS
  • LPTX N/A
  • BLNK N/A
  • Revenue
  • LPTX N/A
  • BLNK $138,728,000.00
  • Revenue This Year
  • LPTX N/A
  • BLNK N/A
  • Revenue Next Year
  • LPTX N/A
  • BLNK $23.10
  • P/E Ratio
  • LPTX N/A
  • BLNK N/A
  • Revenue Growth
  • LPTX N/A
  • BLNK 15.13
  • 52 Week Low
  • LPTX $0.39
  • BLNK $0.87
  • 52 Week High
  • LPTX $4.79
  • BLNK $3.75
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 18.56
  • BLNK 37.29
  • Support Level
  • LPTX $0.40
  • BLNK $0.92
  • Resistance Level
  • LPTX $0.46
  • BLNK $1.04
  • Average True Range (ATR)
  • LPTX 0.03
  • BLNK 0.09
  • MACD
  • LPTX 0.06
  • BLNK 0.01
  • Stochastic Oscillator
  • LPTX 0.00
  • BLNK 12.63

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.

Share on Social Networks: